Meta-analysis---the pooling of results or data across a number of studies---is advocated as a valuable tool in clinical research, not only because it increases the power to detect an association but also because it helps make sense of conflicting results. It is particularly useful in genetic epidemiology, where there has been a massive increase in the number of published primary studies and the proportion of gene-disease associations that have been replicated is disappointingly low ([@bib1]).

Genuine population diversity may explain part of the lack of replication, but the key reasons are probably methodological, due to small sample sizes and bias ([@bib2]). Important biases are publication bias and reporting bias, whereby authors only publish a paper if they obtain statistically significant findings or only report those associations which reach statistical significance. One consequence of this is the "first-study effect," whereby the first study published on a gene-disease association suggests a genetic effect that is not found, or is found with much smaller magnitude, in subsequent studies ([@bib3]). As a result, new findings are generally treated skeptically until they have been replicated. Meta-analysis plays an important role in assessing that replication and in providing an estimate of the size of the genetic effect.

The importance of evidence synthesis in genetic association research is illustrated by [Figure 1](#fig1){ref-type="fig"}, which shows the rapid increase in published meta-analyses of genetic association studies over the last decade. It is less certain whether this increase has been accompanied by an improvement in quality. Previous work evaluating the quality of genetic meta-analyses published up to 2000 showed common flaws in their conduct and reporting ([@bib4]--[@bib6]), which may have led to bias and misleading results.

![Numbers of meta-analyses of genetic association studies published over time, 1966--2007. Articles were obtained through an electronic MEDLINE search, with no limits on publication year or language. No genetic meta-analyses were published before 1993.](amjepidkwp350f01_lw){#fig1}

In this paper, we review the methods used in recent meta-analyses of genetic association studies, assess quality, and compare that quality with the quality of earlier genetic and nongenetic meta-analyses. Based on the findings of the review, we provide practical recommendations for the conduct and reporting of genetic meta-analyses.

MATERIALS AND METHODS
=====================
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### Identification of papers.

We identified papers published in 2005, 2006, and 2007 by searching the HuGE Reviews Archive (<http://www.cdc.gov/genomics/hugenet/reviews_arch.htm>), a database of published meta-analyses of genetic association studies maintained by the Human Genome Epidemiology Network. For each year, we randomly selected 40 papers that were published in English and that reported meta-analyses of summary data on gene-disease associations with binary outcomes. We excluded systematic reviews that did not contain a quantitative synthesis of results and meta-analyses based on individual patient data.

### Data extraction.

Data were extracted using an extraction form (see Web Figure 1, which is posted on the *Journal*'s Web site (<http://aje.oxfordjournals.org/>)) with explicit definitions for each field. The topics covered by the form are listed in [Table 1](#tbl1){ref-type="table"} and include issues of general relevance to all meta-analyses and other issues that are only of concern in genetic epidemiology.

###### 

Main Topics Covered by the Data Extraction Form Used in a Review of 120 Meta-Analyses of Genetic Association Studies Published Between 2005 and 2007

  Topics General to All Meta-Analyses   Topics Specific to Genetic Associations
  ------------------------------------- ------------------------------------------
  Search strategy                       Genetic model
  Inclusion/exclusion criteria          Consideration of polymorphism prevalence
  No. and size of the meta-analyses     Handling of Hardy-Weinberg equilibrium
  Main outcome measure                  Use of biomarkers
  Use of graphical displays             Use of family studies
  Assessment of heterogeneity           
  Fixed- or random-effects models       
  Subgroup analyses                     
  Reporting of study characteristics    
  Consideration of publication bias     

For the papers from 2005, data extraction was performed independently by 2 reviewers. Regular meetings were held to reach consensus, discuss the reasons for disagreements, and refine the definitions of the data extraction fields. The final definitions are given in Web Figure 2 (<http://aje.oxfordjournals.org/>). This iterative process reduced apparent disagreements until we found that remaining discrepancies were due to information being missed by one of the reviewers. For the papers from 2006 and 2007, each article was reviewed by 1 author, and we addressed the problem of overlooked information by using a computer program that searched for a list of keywords in an electronic version of the article (available on request from the authors).

### Indicators of quality.

Although our study was designed to evaluate individual quality components, we also used scores as convenient summaries of the main features of the papers. Some aspects of the meta-analysis of genetic association studies are controversial, but there are some very basic indicators of good practice and good reporting that should always be present. We created 2 quality scores based on such indicators: a "general quality score" that depends on aspects relevant to any meta-analysis and a "genetic quality score" derived from aspects specific to genetics. Twenty-eight quality indicators were identified---19 for general quality and 9 for genetic quality---covering both "positive" and "negative" aspects of the conduct and reporting of genetic meta-analyses. We calculated the 2 quality scores by summing positive factors and subtracting negative factors and scaling the results to lie between 0 and 100, using the theoretical maximum and minimum of the sum.

We then performed a principal component analysis (PCA) ([@bib7]), with the aim of assessing whether 1) indicators would tend to aggregate within the same papers, forming 2 separate clusters for good and poor quality, and 2) indicators subjectively classified as positive and negative would consistently appear in the right cluster of the PCA analysis. The analysis was performed for both general and genetic indicators. We generated new scores by PCA and compared them with the subjective scores, both formally (correlation coefficient) and graphically by plotting one against the other.

The PCA results strongly supported the definition of positive and negative factors of the general score; the correlation between the subjective and PCA-derived scores was very high (Pearson correlation coefficient = 0.98; *P* \< 0.0001). Of the 9 quality indicators for the genetic score, the PCA results supported all but 1 factor, "consideration of biomarkers," which was subjectively classified as positive but was clustered with the other 2 negative factors in the PCA. After removal of this factor, the correlation between subjective and PCA-derived scores increased from 0.86 (*P* \< 0.0001) to 0.96 (*P* \< 0.0001). The indicator was therefore removed from the genetic score. The final items included in both general and genetic scores are listed in [Table 2](#tbl2){ref-type="table"}. The results of the PCA, including the scatterplots of subjective versus PCA-derived scores and the component plots, are shown in Web Figure 3 (<http://aje.oxfordjournals.org/>). The component plots show how each individual quality indicator contributed to the discrimination between good and poor quality. For the general score (Web Figure 3, part a), 3 positive factors (duplicate eligibility checking and/or extraction; forest plot of study-specific results; statistical methods section in paper) and 2 negative factors (search strategy not described; inclusion/exclusion criteria unclear) seemed to capture most of the variability in quality. Corresponding items for the genetic score (Web Figure 3, part c) were 2 positive factors (consideration of impact of genotyping errors; information on linkage disequilibrium) and 2 negative factors (no data on allele/genotype prevalence; no assessment of Hardy-Weinberg equilibrium (HWE)).

###### 

General and Genetic Quality Indicators Used in Quality Scores in a Review of 120 Meta-Analyses of Genetic Association Studies Published Between 2005 and 2007

  Positive Factors                                                              \% of Papers   Negative Factors                                            \% of Papers
  ----------------------------------------------------------------------------- -------------- ----------------------------------------------------------- --------------
  *General Quality Indicators*                                                                                                                             
  Completely reproducible search strategy                                       16             Search methods not described                                14
  Duplicate eligibility checking and/or data extraction                         31             Inclusion/exclusion criteria not reported                   26
  Forest plot of study-specific results                                         78             Designs of primary studies unclear                          20
  Statistical methods section in the paper                                      92             No details on study characteristics                         10
  Formal tests for any interactions                                             10             No details on study-specific results                        18
  Measure of size of heterogeneity (e.g., *I*^2^)                               31             *P* values without effect size estimate                     2
  Reason given for choice of fixed/random effects                               51             No assessment of heterogeneity                              7
  Authors contacted for extra data                                              25             Unclear whether fixed- or random-effects models were used   3
  Study influence assessment                                                    20             No assessment of publication bias                           29
  Quality assessment of individual studies                                      10                                                                         
  *Genetic Quality Indicators*                                                                                                                             
  Reason given for choice of genetic model                                      14             No data on allele/genotype prevalence                       59
  Consideration of impact of genotyping error                                   10             Unclear what genetic model was assumed                      5
  Consideration of impact of population stratification                          14             No assessment of Hardy-Weinberg equilibrium                 59
  Information on linkage disequilibrium                                         25                                                                         
  Information on haplotypes                                                     10                                                                         
  *Quality Score[a](#tblfn1){ref-type="table-fn"}, Mean (Standard Deviation)*                                                                              
  General score                                                                 59.8 (15.8)                                                                
  Genetic score                                                                 30.9 (17.2)                                                                
  Overall score                                                                 51.2 (13.9)                                                                

Quality scores were based on positive and negative indicators of good practice and good reporting. The general quality score depended on aspects relevant to any meta-analysis, and the genetic quality score was derived from aspects specific to genetics. The 2 quality scores were calculated by summing positive factors and subtracting negative factors and scaling the results to lie between 0 and 100, using the theoretical maximum and minimum of the sum.

### Subgroup analyses.

We investigated whether the quality of the meta-analyses might be influenced by characteristics of the published articles, by grouping the papers on the basis of whether the meta-analysis: 1) accompanied a primary study; 2) was a Human Genome Epidemiology (HuGE) review; 3) appeared in a general medicine, genetics, or specialty journal; or 4) appeared in a journal with a high impact factor.

Comparisons with previous work
------------------------------

We searched the literature to identify previous reports of the quality of published meta-analyses in order to look for evidence of methodological improvement over time and for differences between genetic and nongenetic meta-analyses.

We considered all papers included in MEDLINE (US National Library of Medicine) that had been published between 1966 and August 2008, using the following search strategy: (meta-analys\* *or* systematic review\*) *and* (quality *or* evaluat\* *or* assessment *or* survey *or* appraisal *or* methodolog\*), with the search field limited to the title of the article. Reference lists of all relevant papers were scanned for further potential studies. We limited inclusion to reviews published in English that had assessed more than 10 meta-analyses. Since different criteria have been used to evaluate the quality of meta-analyses, producing problems of comparability, we included only those reviews which provided information on at least 2 of the following 5 items: 1) reporting of the search strategy; 2) reporting of the inclusion criteria; 3) reporting of the pooling methods; 4) evaluation of statistical heterogeneity; and 5) evaluation of publication bias.

RESULTS
=======
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### Selection of studies.

The meta-analysis articles were classified in the HuGE Reviews Archive by area of medicine, as papers on: neoplasms (*n* = 28); endocrine, nutritional, and metabolic diseases and immunity disorders (*n* = 25); diseases of the circulatory system (*n* = 18); diseases of the nervous system and sense organs (*n* = 16); mental disorders (*n* = 12); and other topics (*n* = 21). Of the 120 papers identified, 74% reported results of 1 or more meta-analyses, while in the other 26%, investigators reported results from their own primary study, accompanied by a meta-analysis based on one of their main findings. The median number of primary studies included in a paper was 13 (interquartile range, 8--22), while the median number of separate meta-analyses performed was 2 (interquartile range, 1--3; range, 1--26). Each of these meta-analyses included 2--119 primary studies. The median size of the largest meta-analysis in each of the 120 articles was 11 studies (interquartile range, 8--18). Among the 96 papers that clearly reported the design of the studies included, 5 meta-analyzed family-based studies, another 4 combined family studies with population studies, and the rest analyzed only population-based studies, including case-control, cohort, and cross-sectional studies or a mixture of the 3.

### Indicators of quality in conduct or reporting.

Results for the individual quality indicators are shown in [Table 2](#tbl2){ref-type="table"}. Detailed results on all of the other items considered, for the whole sample and by subgroup, are shown in Web Tables 1--6 (<http://aje.oxfordjournals.org/>). Overall, the papers scored better on general indicators than on genetic indicators, although basic issues such as reporting of inclusion/exclusion criteria and assessment of publication bias were ignored by more than one-fourth of the meta-analyses. In approximately one-third of the papers, investigators had performed duplicate checking of eligibility/data extraction and estimated the magnitude of the between-study heterogeneity along with the test, suggesting thoroughness in the conduct of the meta-analysis. Study quality assessment was performed in only 12 meta-analyses. These analyses used different sets of criteria, usually based on checklists developed for the evaluation of epidemiologic studies, with the addition of items specific to genetics. In only 9 meta-analyses did investigators evaluate the first-study effect.

### Primary study effect.

Whether the meta-analysis was the primary focus of the article or was an accompaniment to the authors' own primary study had a large impact on quality. We accessed supplementary materials posted on a journal\'s or author\'s Web site whenever such materials were mentioned. [Table 3](#tbl3){ref-type="table"} shows the factors that varied significantly (*P* \< 0.05) between meta-analyses published with and without an accompanying primary study. The factors all pointed to poorer quality when the meta-analysis was not the primary focus, with strong differences for most aspects of the conduct and reporting of the meta-analysis. The quality was much lower for both the general quality indicators and the genetic quality indicators, with differences of 36% (*P* \< 0.0001) and 35% (*P* \< 0.001), respectively. In more than half of the meta-analyses that accompanied a primary study, the investigators did not even specify what databases they had searched.

###### 

Quality Indicators That Varied Significantly (*P* \< 0.05) Between Papers With a Meta-Analysis Only and Papers With a Meta-Analysis Accompanying a Primary Study in a Review of 120 Meta-Analyses of Genetic Association Studies Published Between 2005 and 2007

  Quality Indicator                                Papers With M-A Only (*n* = 89)   Papers With M-A + Primary Study (*n* = 31)   *P* Value[a](#tblfn2){ref-type="table-fn"}                 
  ------------------------------------------------ --------------------------------- -------------------------------------------- -------------------------------------------- ------------- ----------
  General indicators of quality                                                                                                                                                              
      Search strategy                                                                                                                                                                        
          Databases listed                         100                                                                            45                                                         \<0.001
          End date stated                          93                                                                             35                                                         \<0.001
          Search terms listed                      93                                                                             42                                                         \<0.001
      Inclusion/exclusion criteria reported        92                                                                             29                                                         \<0.001
      Duplicate eligibility assessment             17                                                                             0                                                          0.011
      Duplicate data extraction                    36                                                                             3                                                          \<0.001
      Use of random-effects models                 87                                                                             48                                                         \<0.001
      Heterogeneity test                           99                                                                             77                                                         \<0.001
      Measure of size of heterogeneity             36                                                                             16                                                         0.044
      Primary study sizes reported                 81                                                                             52                                                         0.004
      Primary study disease definitions reported   56                                                                             6                                                          \<0.001
      Primary study ethnicity/location reported    88                                                                             42                                                         \<0.001
      Graphical evaluation of publication bias     55                                                                             23                                                         0.002
      Statistical test of publication bias         70                                                                             26                                                         \<0.001
      Cumulative meta-analysis                     20                                                                             3                                                          0.024
      Study influence assessment                   25                                                                             6                                                          0.036
  Genetic indicators of quality                                                                                                                                                              
      Testing for Hardy-Weinberg equilibrium       49                                                                             16                                                         0.001
      Allele/genotype counts reported              64                                                                             42                                                         0.036
      Data on prevalence of polymorphism(s)        51                                                                             13                                                         \<0.001
  Quality score[b](#tblfn3){ref-type="table-fn"}                                                                                                                                             
      General score                                                                  66.1 (10.6)                                                                               41.8 (14.5)   \<0.0001
      Genetic score                                                                  34.0 (18.0)                                                                               22.2 (11.0)   \<0.001
      Overall score                                                                  56.6 (10.2)                                                                               36.0 (12.0)   \<0.0001

Abbreviations: M-A, meta-analysis; SD, standard deviation.

*P* values were based on a 2-tailed Fisher\'s exact test for quality indicators and the Mann-Whitney *U* test for quality scores.

Quality scores were based on positive and negative indicators of good practice and good reporting. The general quality score depended on aspects relevant to any meta-analysis, and the genetic quality score was derived from aspects specific to genetics. The 2 quality scores were calculated by summing positive factors and subtracting negative factors and scaling the results to lie between 0 and 100, using the theoretical maximum and minimum of the sum.

### Quality of HuGE reviews.

None of the HuGE reviews accompanied a primary study, so they were compared with the other articles that did not include a primary study. There were 16 (18%) HuGE reviews, 14 published in the *American Journal of Epidemiology* and 2 in *Genetics in Medicine*, and 73 comparator articles.

There was no significant difference in general quality scores between HuGE reviews and other meta-analyses. For the genetic score, there was a nonsignificant trend towards better quality in HuGE reviews (16% difference; *P* = 0.090). This reflected a higher proportion of meta-analyses in which investigators tested for departures from HWE (63% vs. 47%; *P* = 0.281) and a higher proportion of papers in which investigators considered the possibility of genotyping errors in the primary studies (25% vs. 8%; *P* = 0.076). Half of the HuGE reviews, as compared with one-fifth of the others (*P* = 0.021), used pairwise comparisons that do not require the assumption of a genetic model. The tendency toward better reporting of primary study characteristics in HuGE meta-analyses can be seen in several features (Web Tables 3 and 4), particularly for disease definition (81% vs. 51%; *P* = 0.029) and for evaluation of the prevalence of the genetic variant in the population (81% vs. 44%; *P* = 0.011).

###### 

Results of Reviews on Quality of Meta-Analyses Across Different Fields of Research

  Authors and Year (Ref. No.)                                           Field of Research (Type of Primary Studies)                           No. of M-A\'s          Publication Date(s) of M-A\'s   Quality Indicator (% of M-A\'s Fulfilling the Criterion)                                                                                    
  --------------------------------------------------------------------- --------------------------------------------------------------------- ---------------------- ------------------------------- ---------------------------------------------------------- ------------------------------------- ------------------------------------- ---- ----
  Current review                                                        Genetic epidemiology (genetic association studies)                    120                    2005--2007                      86                                                         74                                    97                                    93   71
  Attia et al., 2003 ([@bib4])                                          Genetic epidemiology (genetic association studies)                    37                     1991--2000                      65                                                         49                                    97                                    76   19
  De Vito et al., 2007 ([@bib37])[a](#tblfn4){ref-type="table-fn"}      Vaccinology (all study designs)                                       121                    1991--2007 (February)           87                                                         79                                    79                                    67   26
  Junhua et al., 2007 ([@bib38])                                        Traditional Chinese medicine (NS)                                     36                     1978--2006                      78                                                         81                                    67                                    NR   NR
  Gerber et al., 2007 ([@bib39])[b](#tblfn5){ref-type="table-fn"}       Any field (mostly RCTs)                                               272                    1993--2002                      85                                                         NR                                    100                                   85   21
  Sheik et al., 2007 ([@bib40])[a](#tblfn4){ref-type="table-fn"}        Maternal medicine (NS)                                                39 Cochrane            2001--2006                      97                                                         100                                   NR                                    NR   NR
  29 others                                                             90                                                                    59                     NR                              NR                                                         NR                                                                               
  Boluyt et al., 2006 ([@bib41])                                        Asthma (randomized and quasi-randomized trials)                       14 Cochrane            2000--2006                      100                                                        100                                   100                                   74   NR
  9 others                                                              1992--2005                                                            89                     78                              67                                                                                                                                          
  Collier et al., 2006 ([@bib42])[a](#tblfn4){ref-type="table-fn"}      Dermatology (mostly RCTs)                                             28 Cochrane            1999--2004                      100                                                        96                                    71                                    NR   NR
  10 others                                                             1999--2005                                                            90                     70                              60                                                         NR                                    NR                                         
  Flores-Mir et al., 2006 ([@bib43])[a](#tblfn4){ref-type="table-fn"}   Orthodontics (NS)                                                     16                     2000--2004                      88                                                         100                                   NR                                    NR   NR
  Golder et al., 2006 ([@bib44])[a](#tblfn4){ref-type="table-fn"}       Adverse effects (all study designs)                                   256                    1994--2005                      77                                                         NR                                    NR                                    88   NR
  Jorgensen et al., 2006 ([@bib45])                                     Any field (mostly RCTs)                                               24 Cochrane            1996--2003                      96                                                         100                                   100                                   NR   NR
  24 others                                                             75                                                                    83                     96                              NR                                                         NR                                                                               
  Shea et al., 2006 ([@bib46])[a](#tblfn4){ref-type="table-fn"}         Musculoskeletal diseases                                              57 Cochrane            Up to 2002                      88                                                         100                                   95                                    NR   NR
  Shea et al., 2006 ([@bib47])[a](#tblfn4){ref-type="table-fn"}         Any field (mostly RCTs)                                               53 Cochrane original   Up to 2002                      81                                                         98                                    89                                    NR   NR
  53 Cochrane updated                                                   87                                                                    91                     83                              NR                                                         NR                                                                               
  Delaney et al., 2005 and 2007 ([@bib48], [@bib49])                    Critical care medicine (NS)                                           47 Cochrane            1994--2003                      100                                                        98                                    81                                    NR   NR
  92 others                                                             91                                                                    78                     78                              NR                                                         NR                                                                               
  Dixon et al., 2005 ([@bib50])                                         General surgical literature (NS)                                      51                     1997--2002                      67                                                         70                                    67                                    NR   NR
  Lawson et al., 2005 ([@bib51])                                        Conventional medicine and complementary/alternative medicine (RCTs)   105 conventional       Up to 1999                      49                                                         74                                    77                                    NR   15
  25 complementary                                                      68                                                                    100                    84                              NR                                                         16                                                                               
  Palma and Delgado-Rodriguez, 2005 ([@bib52])                          Cardiovascular (all study designs)                                    225                    1990--2002                      NR[c](#tblfn6){ref-type="table-fn"}                        NR[c](#tblfn6){ref-type="table-fn"}   NR[c](#tblfn6){ref-type="table-fn"}   83   11
  Moher et al., 2002 ([@bib53])                                         Pediatric alternative and conventional medicine (NS)                  66                     NS--2001                        52                                                         64                                    41                                    38   17
  Shea et al., 2002 ([@bib54])                                          Any field (RCTs)                                                      52 Cochrane            1993--1996                      31                                                         74                                    98                                    29   8
  52 others                                                             1990--1995                                                            64                     46                              85                                                         65                                    17                                         
  Bhandari et al., 2001 ([@bib55])                                      Orthopedic surgery (RCTs and observational studies)                   40                     1984--1999                      83                                                         78                                    70                                    NR   NR
  Choi et al., 2001 ([@bib56])                                          Anesthesia (NS)                                                       82                     1989--1999                      73                                                         81                                    82                                    35   5
  Kelly et al., 2001 ([@bib57])                                         Emergency medicine (NS)                                               29                     1990--1998                      55                                                         69                                    74                                    NR   NR
  Fishbain et al., 2000 ([@bib58])                                      Chronic pain treatment (NS)                                           16                     1988--1998                      NR                                                         88                                    NR                                    38   19
  Jadad et al., 2000 ([@bib59])                                         Asthma (RCTs and observational studies)                               50                     1988--1998                      66                                                         60                                    52                                    40   16
  Jadad et al., 1998 ([@bib60])                                         Any field of medicine (RCTs)                                          36 Cochrane            1995                            NR                                                         90                                    NR                                    47   NR
  39 others                                                             46                                                                    54                                                                                                                                                                                                 
  Jadad et al., 1996 ([@bib61])                                         Pain research (RCTs and observational studies)                        80                     1980--1993                      61                                                         73                                    71                                    NR   NR
  Sacks et al., 1996 ([@bib62])                                         Any field of medicine (RCTs)                                          58                     1987--1990                      69                                                         67                                    78                                    47   41
  Assendelft et al., 1995 ([@bib63])                                    Spinal manipulation (RCTs)                                            51                     1977--1993                      27                                                         35                                    NR                                    NR   NR
  Sacks et al., 1987 ([@bib64])                                         Any field of medicine (RCTs)                                          86                     1955--1986                      35                                                         44                                    66                                    23   2

Abbreviations: M-A\'s, meta-analyses; NR, not reported; NS, not stated; RCTs, randomized clinical trials.

Included both systematic reviews and M-A\'s, with data on quality indicators provided for the whole sample.

M-A\'s were selected from 4 general journals (impact factors ranged from 9.7 to 28.6) and 4 specialist journals (impact factors ranged from 3.6 to 12.8).

Included in this review were only M-A\'s which reported search strategy, inclusion criteria, and methods for pooling.

### Impact factor and journal type.

The 31 meta-analyses that accompanied primary studies were generally of poor quality and were predominantly published in the specialist journals (81%). Among meta-analyses in papers without a primary study, no differences in either general or genetic quality were found between the 3 types of journals. Detailed results are shown in Web Tables 5 and 6.

We performed a regression analysis to assess whether the quality scores varied with the (log) impact factor of the journal. The overall quality score among the 31 meta-analyses that accompanied primary studies was positively associated with the impact factor of the journals (*P* = 0.01), with such an association being mainly confined to the general quality indicators. Among the other 89 articles, neither the general quality nor the genetic quality showed any trend with impact factor.

Comparison with previous work
-----------------------------

### Previous reviews.

The electronic search yielded 957 "hits," from which 73 full-text articles were obtained and evaluated for eligibility. Four papers were added after cross-checking of reference lists, and 1 paper was added because it was known to the authors. Fifty papers were subsequently excluded, most because of the low number of meta-analyses considered (≤10) or the reporting of only 1 of the 5 criteria. A flow chart detailing inclusion and reasons for exclusion is presented in Web Figure 4 (<http://aje.oxfordjournals.org/>). [Table 4](#tbl4){ref-type="table"} presents the results of the remaining 29 articles, reporting on 28 reviews. The reviews considered 16--272 meta-analyses. Only 1 review considered the meta-analysis of genetic association studies, while most of the others focused on randomized clinical trials. The Oxman and Guyatt scale, also known as the Overview Quality Assessment Questionnaire ([@bib8]), was the most commonly used quality scale (62%), although it was often accompanied by information on additional quality indicators.

### Trend in quality over time.

By comparing our findings on recently published meta-analyses with those of Attia et al. ([@bib4]) on 37 meta-analyses published before 2000, we can see improvement over time in both reporting and conduct. Reporting of the search methods increased from 65% in older meta-analyses to 86% in recent meta-analyses (*P* = 0.008), and the same was found for reporting of inclusion criteria, which increased from 49% to 74% (*P* = 0.005). Improvement in the conduct of meta-analyses is suggested by a substantial increase in the assessment of heterogeneity (from 76% to 93%; *P* = 0.005) and an extraordinary increase in the evaluation of publication bias (from 19% to 71%; *P* \< 0.001). None of the meta-analyses published before 2000 used a formal statistical test to evaluate the presence of publication bias, as compared with 58% of recent meta-analyses, the majority of which used Egger\'s test (introduced in 1997).

Improvement in genetic quality factors is less marked. HWE was tested in individual studies in only 24% of the meta-analyses published before 2000 versus 41% of those included in our review (*P* = 0.081). No difference was found for the choice of the genetic model, with results being based solely on a per-allele analysis in 24% of the papers versus 21% (*P* = 0.653). Interestingly, in our review, only 6 of the 25 papers (24%) that used solely a per-allele analysis performed a test for HWE, even though HWE is required for such a per-allele test. Similarly, only 1 of those 25 (4%) provided a reason for choosing an additive genetic model. For papers using per-genotype analyses, the proportion of those assuming a specific genetic model did not change: 33% in older meta-analyses versus 27% in recent ones (*P* = 0.53). Among these meta-analyses, the proportion of papers in which investigators provided justification for their model choice was even lower for recent meta-analyses than for older ones (25% vs. 67%; *P* = 0.016).

### Comparison with quality in other fields.

The results shown in [Table 4](#tbl4){ref-type="table"} suggest that the quality of meta-analysis across different fields of research varies widely. When comparing meta-analyses published before 2002 with the more recent ones, a time trend of improvement is noticeable for all items, apart from the assessment of publication bias. This important issue seems to be consistently overlooked in meta-analysis across fields and over time, with the exception of the papers included in our review. No clear difference is evident between reviews on meta-analyses of randomized clinical trials and reviews which include meta-analyses of other study designs. The quality of Cochrane systematic reviews and meta-analyses is reported to be higher, with the exception of the 2002 paper by Shea et al. ([@bib54]), where Cochrane papers were found to score no better, and for some quality items even worse, than others ([Table 4](#tbl4){ref-type="table"}). The authors suggested that this finding was due to low quality of reporting rather than conduct, and they pointed out how the Cochrane Collaboration had taken steps to improve the quality of its reviews in the period since their study ([@bib54]).

DISCUSSION
==========

The general quality of current genetic meta-analyses is very variable, although on average it is similar to that observed in other fields of medicine, and there is evidence of an improvement since Attia et al.'s earlier review ([@bib4]). Recognition of potential problems, such as publication bias, is not always accompanied by appropriate action. The quality of the handling of specifically genetic factors is disappointingly low and does not seem to be improving. HuGE reviews scored better than the other analyses in this respect, but the comparison is hard to interpret because of the relatively small numbers.

Quality was markedly poorer in the 26% of the meta-analyses that accompanied the report of a primary study. This may reflect partly the expertise of the authors and the time available for performing the meta-analysis and partly the amount of space available in a given journal. Investigators sometimes add a meta-analysis in order to put their results into context. Although this is, in principle, a way of strengthening the evidence, it can lead to a "quick-and-dirty" meta-analysis. A poorly conducted or poorly reported meta-analysis is of little scientific use and may mislead. If space is a problem, details should be posted on a Web site.

The use of quality scores has limitations, in the same way as shown for the quality assessment of primary studies included in systematic reviews and meta-analyses ([@bib9]). Our interest was to evaluate individual quality components, and we used scores only as convenient summaries for comparing quality across different types of meta-analyses. We created 2 quality scores, one with general quality indicators and the other with quality indicators specific to genetics, based on our subjective judgment. It is interesting that when a more objective approach to the assessment of quality was applied using PCA, the correspondence of the PCA-derived scores with our subjective scores was very high. The only exception was an item that we had selected as a genetic indicator of good quality---the consideration of biomarkers or intermediate phenotypes in the paper---which proved not to be a good marker of quality in the PCA. When this item was deleted from the genetic score, the correlation between "subjective" and "objective" scores was 96%. The PCA results suggest that the quality indicators used in this paper, when taken as a set, can discriminate well between meta-analyses of good and poor quality, even if individually they have differing relevance and impact on quality. The results of the PCA also suggest that fewer indicators might be equally able to discriminate between good and poor quality for both the general and the genetic aspects of meta-analysis.

Recommendations
---------------

### Stating the rationale for the meta-analysis.

We found that the rationale for the meta-analysis was often not stated clearly. A meta-analysis might be exploratory or it might, for instance, be intended to replicate or support a result from a primary study or to evaluate sources of heterogeneity.

When a finding from a primary study is conclusive, the aim of a meta-analysis may be to see whether the same association holds in other populations; when it is not conclusive, the aim might be to see whether it becomes so when combined with evidence from other studies. In the former case, the meta-analysis would not include the primary study, while in the latter it would. However, in our review, all 31 meta-analyses which accompanied a primary study included that study in the meta-analysis.

### Identification and selection of studies.

Although the majority of the authors in our review described their search strategy, few of them did so in a way that allowed reproducibility. Details on the search strategy could be made available as Web material if space were limited. The numbers of papers identified at each stage should be reported, possibly using the flow diagram suggested in the QUOROM statement ([@bib10]). In our review, fewer than one-fourth of the meta-analyses provided this information.

There is no consensus on whether combining family- and population-based studies within a single meta-analysis is appropriate, the main concern being that gene-gene and gene-environment interactions might play different roles in the 2 types of studies. However, a number of authors have argued in favor of their combination ([@bib11]--[@bib13]), and this is recommended in the *HuGE Review Handbook* ([@bib14]) when the available evidence is limited. Family studies based on the transmission disequilibrium test can be combined with population-based studies that use a per-allele approach, provided that the assumptions of additivity and HWE hold. When family- and population-based studies are combined, it is important to perform a sensitivity analysis.

Study identification is time-consuming, which may explain why only 13% of the papers in our review included a duplicate reading of the titles and abstracts. However, this is an important step that protects against selection bias. The selected articles should be read and information extracted onto a predesigned data extraction form, again in duplicate. In the meta-analyses included in our review, duplicate data extraction was performed in 28% of all papers and 50% of the HuGE reviews.

### Choice of the genetic model.

A key decision in any meta-analysis is which genetic model to adopt. In our review, 1 in 5 papers used a per-allele analysis. This requires an additive model and HWE ([@bib15]). However, these assumptions are often ignored. In only 1 (4%) of the papers that relied on a per-allele analysis did investigators provide a reason, and in only one-fourth did they test for HWE. For the per-genotype approach, a genetic model was assumed in approximately one-fourth of the papers reviewed. The assumption of a genetic model increases statistical power, but there must be a priori knowledge to support the choice. In practice, there is often only poor-quality information on the genetic model, especially when the allele frequency is low. Among meta-analyses that assumed a genetic model, in only one-fourth of the papers did the authors provide justification for their choice. Assuming a "wrong" genetic model is a potential source of bias ([@bib16]). When the underlying genetic model is unknown, it is better to use pairwise comparisons of the 3 genotypes, and the loss of power may be limited through the use of a bivariate meta-analysis ([@bib17]). Alternatively, data can be utilized more efficiently using a "genetic model-free" approach, which estimates the genetic model from the data ([@bib16], [@bib17]).

### Assessment of heterogeneity.

Assessing the presence of between-study heterogeneity is a crucial step in any meta-analysis. In the vast majority of the meta-analyses reviewed, investigators performed a statistical test for heterogeneity, although only one-third of them estimated its magnitude. Testing for heterogeneity alone is unsatisfactory, not only because it does not provide evidence on the extent of the problem but also because of the low power of the tests. The magnitude of heterogeneity can be directly measured by the between-study variance. In the meta-analyses reviewed, heterogeneity was mainly quantified using *I*^2^, a measure proposed by Higgins et al. ([@bib18]) and defined as the percentage of total variation in study estimates explained by heterogeneity rather than sampling error. However, as Higgins and Thompson ([@bib19]) have pointed out, *I*^2^ better describes the impact of heterogeneity on the meta-analysis than the magnitude of heterogeneity.

If the studies are heterogeneous in a way not anticipated in the hypothesis, the first priority should be to investigate the causes. Perhaps heterogeneity is due to a few aberrant studies, or perhaps it is due to geographic or methodological factors. This can be evaluated by means of meta-regression or by using subgroup analyses accompanied by formal testing, although statistical significance has to be interpreted in the light of the low power of interaction tests ([@bib20]). In the review, subgroup analyses were performed in 70% of the meta-analyses, but only 10% formally tested for interaction. Meta-regression based on study-level characteristics was used in 18% of the papers, while patient-level characteristics were used in 13%. Without individual patient data, the use of patient-level characteristics in meta-regression should be discouraged, as it is difficult to interpret ([@bib21]) and has very little power to explain heterogeneity ([@bib22]).

Ideally, study quality should be investigated as a cause of heterogeneity. Our review shows that this is rarely done, perhaps because there is no consensus on the best quality scoring model. Although many authors have proposed checklists ([@bib1], [@bib23]--[@bib26]), no synthesis of this work has been carried out.

### Use of random effects.

When unanticipated heterogeneity cannot be explained, a decision needs to be made on whether to continue with the analysis using a random-effects model ([@bib27]) or to refrain from pooling. Forcing a random-effects meta-analysis in the presence of large heterogeneity can produce an average estimate that is meaningless. An extreme example of this is genetic "flip-flop" ([@bib28], [@bib29]), where results from primary studies are significant but point in opposite directions. A meta-analysis which combines such studies might misleadingly suggest a lack of genetic effect. There are no clear guidelines on how much heterogeneity is allowable, but as a rough guide, we would suggest only using a random-effects model if the standard deviation of the between-study variation is less than 25% of the pooled effect size---for instance, a log odds ratio.

### Evaluation of HWE.

HWE should be investigated in the individual studies, since deviation from HWE may reflect methodological problems, such as genotyping error, population stratification, or selection bias ([@bib30]). Because of low statistical power, it is advisable to measure the magnitude of the deviation from HWE as well as its significance. In our review, HWE was assessed in 41% of the recent papers, and the assessment was limited to statistical testing, apart from 3 meta-analyses in which the magnitude of the deviation was used to adjust the final pooled estimate of the genetic effect. We suggest that lack of HWE should be treated as a reason for further investigation of a primary study rather than as grounds for its exclusion ([@bib4], [@bib31]).

### Evaluation of publication bias.

Although publication bias was more frequently considered in our review than in most others, in only half of the papers did investigators report using a funnel plot, and slightly more than half reported using a statistical test. Graphical assessment of the possible presence of publication bias is simple and useful. However, judgment based only on visual inspection of funnel plots tends to be inaccurate, as suggested by empirical evaluation ([@bib32]), and funnel plots are best used in conjunction with a test. A number of tests for publication bias have been proposed, and the choice between them depends on characteristics of the meta-analysis ([@bib33]). If publication bias is suspected, it may be sensible to concentrate the analysis on the larger studies or to model the dependence on sample size ([@bib34]). Publication might be faster for studies with positive findings (time-lag bias) ([@bib35]), and the use of cumulative and recursive meta-analysis can help detect time trends in effect estimates ([@bib36]). In our review, cumulative meta-analysis was performed in only 16% of the papers.

### Reporting of study-specific data.

Generally, with the exception of HuGE reviews, the reporting of study characteristics needs to be improved. Neither genotype nor allele counts were reported in nearly half of the meta-analyses. Additional material can easily be placed on a Web page, and journal editors and reviewers should encourage this. Other information that should be reported includes the prevalence of the risk allele, linkage disequilibrium in the region, genotyping error rates, and any haplotypes or biomarkers that have been investigated. With the exception of the prevalence of the polymorphisms, which was reported in the majority of HuGE reviews and one-third of the others, such data were rarely given.

Conclusions
-----------

Although the general quality of genetic meta-analyses is similar to that observed in other fields of medicine and shows improvement over time, the quality of the handling of specifically genetic factors is disappointingly low and does not seem to be improving. This is perhaps not surprising, given the lack of consensus in the theoretical literature on the best methods to use. The tendency towards better quality of HuGE reviews suggests that the *HuGE Review Handbook* ([@bib14]) has positively influenced the conduct and reporting of such meta-analyses, but there is still a long way to go. Meta-analysis features very highly in the hierarchy of evidence, so it is incumbent on investigators performing meta-analyses to be as methodologically rigorous as possible. Development of formal, detailed consensus guidelines, similar to those of QUOROM ([@bib10]), would be helpful.
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:   Human Genome Epidemiology
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:   Hardy-Weinberg equilibrium
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:   principal component analysis
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